

Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study



Aung Pyae Phyo, Standwell Nkhoma, Kasia Stepniewska, Elizabeth A Ashley, Shalini Nair, Rose McGready, Carit ler Moo, Salma Al-Saai, Arjen M Dondorp, Khin Maung Lwin, Pratap Singhasivanon, Nicholas P J Day, Nicholas J White, Tim J C Anderson, François Nosten

Summary

Background Artemisinin-resistant falciparum malaria has arisen in western Cambodia. A concerted international effort is underway to contain artemisinin-resistant *Plasmodium falciparum*, but containment strategies are dependent on whether resistance has emerged elsewhere. We aimed to establish whether artemisinin resistance has spread or emerged on the Thailand–Myanmar (Burma) border.

Methods In malaria clinics located along the northwestern border of Thailand, we measured six hourly parasite counts in patients with uncomplicated hyperparasitaemic falciparum malaria ($\geq 4\%$ infected red blood cells) who had been given various oral artesunate-containing regimens since 2001. Parasite clearance half-lives were estimated and parasites were genotyped for 93 single nucleotide polymorphisms.

Findings 3202 patients were studied between 2001 and 2010. Parasite clearance half-lives lengthened from a geometric mean of 2.6 h (95% CI 2.5–2.7) in 2001, to 3.7 h (3.6–3.8) in 2010, compared with a mean of 5.5 h (5.2–5.9) in 119 patients in western Cambodia measured between 2007 and 2010. The proportion of slow-clearing infections (half-life ≥ 6.2 h) increased from 0.6% in 2001, to 20% in 2010, compared with 42% in western Cambodia between 2007 and 2010. Of 1583 infections genotyped, 148 multilocus parasite genotypes were identified, each of which infected between two and 13 patients. The proportion of variation in parasite clearance attributable to parasite genetics increased from 30% between 2001 and 2004, to 66% between 2007 and 2010.

Interpretation Genetically determined artemisinin resistance in *P. falciparum* emerged along the Thailand–Myanmar border at least 8 years ago and has since increased substantially. At this rate of increase, resistance will reach rates reported in western Cambodia in 2–6 years.

Funding The Wellcome Trust and National Institutes of Health.

Introduction

Artemisinin combination treatments are the recommended first-line therapy for falciparum malaria. *Plasmodium falciparum* parasites with reduced in-vivo susceptibility to artemisinin derivatives (eg, artesunate) have emerged in western Cambodia.^{1–3} This finding threatens worldwide initiatives to control and eliminate malaria.⁴ Resistance to the previous mainstays of anti-malarial treatment—namely, chloroquine and sulfadoxine–pyrimethamine—also arose in western Cambodia^{5–7} and spread across southeast Asia into Africa, resulting in the deaths of millions of children.^{8,9} If resistance to artemisinin is confined to the Cambodia–Thailand border, regional elimination of falciparum malaria will probably be necessary for containment.^{10,11} However, if resistant parasites have already spread or emerged elsewhere, then the containment zone will need to be extended and the strategy reconsidered.^{3,7}

Artemisinin resistance is characterised by slow parasite clearance.^{1,2,12} Clearance (assessed by microscopy) of sensitive *P. falciparum* is achieved within 2 days in 95% of patients,¹³ whereas artemisinin-resistant infections remain slide-positive for 3 or more days; treatment failure is more common in such infections after artemisinin combination treatment. High-grade artemisinin resistance has not been

reported. Laboratory studies and mathematical modelling suggest that slow clearance of resistant parasites mainly results from decreased susceptibility of ring-stage parasites to artemisinin and its derivatives.¹⁴ No laboratory assays reliably identify artemisinin-resistant parasites.² Patients from western Cambodia with similar parasite clearance rates are infected with genetically indistinguishable parasite clones, suggesting that parasite genetics have a central role in determination of this trait,¹⁵ although the genes responsible are unknown.

On the northwestern border of Thailand, 800 km from western Cambodia, treatment failure rates with artesunate and mefloquine combinations have increased.¹⁶ In this area, patients without signs of severity but with more than 4% parasitaemia (ie, parasites present in 4% or more of red blood cells) are given oral artesunate regimens, which have proven superior to intravenous quinine.^{17,18} High admission parasitaemias allow for accurate assessment of parasite clearance rates. To assess whether artemisinin resistance has emerged in this strategically important area, we analysed over 10 years the longitudinal changes in parasite clearance rates in a large prospective series of hyperparasitaemic patients given artesunate. Parasites were genotyped to establish the contribution of parasite genetics to parasite clearance rates.

Published Online

April 5, 2012

DOI:10.1016/S0140-6736(12)60484-X

See Online/Comment

DOI:10.1016/S0140-6736(12)60488-7

Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand (A P Phyo MD, K Stepniewska PhD, E A Ashley MD, R McGready MD, A M Dondorp MD, P Singhasivanon MD, N P J Day FRCP, N J White FRS, F Nosten MD); Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand (A P Phyo, E A Ashley, R McGready, C ler Moo, K Maung Lwin MD, F Nosten); Texas Biomedical Research Institute, San Antonio, Texas, USA (S Nkhoma PhD, S Nair MSc, S Al-Saai MSc, T J C Anderson PhD); Centre for Tropical Medicine, Churchill Hospital, Oxford, UK (K Stepniewska, E A Ashley, R McGready, A M Dondorp, N P J Day, N J White, F Nosten); and Worldwide Antimalarial Resistance Network, Oxford, UK (K Stepniewska)

Correspondence to: Prof François Nosten, Shoklo Malaria Research Unit, PO Box 46, Mae Sot, Tak, Thailand 63110
francois@tropmedres.ac

Methods

Study site and patients

Data were obtained from patients with a high parasite count (>4% infected red blood cells) but no signs of severe malaria routinely admitted to malaria clinics run by the Shoklo Malaria Research Unit, which span a 150 km

See Online for appendix

Panel 1: Heritability

Measurement of heritability—ie, the proportion of variance in a trait that is explained by genetics—is widely used in human and agricultural genetics.²⁰ This measure is especially useful when the loci underlying trait variation are unknown and when the genetic and environmental contributions to trait variation are uncertain, as in the case of parasite clearance rates. Heritability can be measured in *Plasmodium falciparum* by comparing trait variation in genetically indistinguishable parasites infecting different patients, just as heritability in people can be measured with identical twins. This approach uses the fact that such parasites are frequently recovered from several patients in southeast Asian countries because of low transmission and consequently high rates of inbreeding.¹⁵ When resistance genes spread within a parasite population, heritability increases because genetic determinants have a growing role in determination of trait variation.

	N	Geometric mean parasite clearance half-life (95% CI)	Range	% change (95% CI)*	p value
Artesunate and mefloquine treatment†				-4.3 (-7.8 to -0.7)	0.018
No	640	3.267 (3.162–3.374)	0.730–11.613		
Yes	2266	3.125 (3.072–3.180)	0.588–12.545		
Admission‡				3.4 (2.8 to 4.0)‡	<0.0001
2001	156	2.628 (2.535–2.725)	1.079–7.484		
2010	156	3.674 (3.561–3.791)	1.454–9.111		
Days fever				9.0 (5.7 to 12.4)	<0.0001
<3 days	1467	3.030 (2.966–3.095)	0.847–11.613		
≥3 days	1401	3.301 (3.230–3.374)	0.588–12.545		
Admission gametocytaemia				13.9 (8.7 to 19.4)	<0.0001
No	2563	3.108 (3.058–3.158)	0.588–12.545		
Yes	343	3.540 (3.387–3.700)	0.730–10.146		
Admission haematocrit				-9.2 (-12.8 to -5.5)	<0.0001
<30%	511	3.417 (3.295–3.543)	0.730–9.804		
≥30%	2395	3.103 (3.051–3.155)	0.588–12.545		
Sex				0.5 (-2.6 to 3.8)	0.74
Female	1083	3.145 (3.068–3.225)	0.730–11.613		
Male	1823	3.162 (3.102–3.224)	0.588–12.545		
History of malaria				-3.8 (-6.8 to -0.8)	0.014
No	1301	3.235 (3.162–3.310)	0.805–12.545		
Yes	1511	3.111 (3.046–3.177)	0.588–11.613		
Parenteral rescue treatment				19.7 (13.8 to 25.9)	<0.0001
No	2616	3.100 (3.051–3.149)	0.588–11.613		
Yes	290	3.710 (3.537–3.892)	0.906–12.545		
Blood transfusion				11.8 (3.0 to 21.4)	0.008
No	2738	3.150 (3.101–3.200)	0.588–12.545		
Yes	104	3.522 (3.248–3.820)	1.260–9.804		

(Continues on next page)

region of the northwestern border of Thailand. Maela (refugee camp) and Wang Pha village are north of Mae Sot town (where the research unit is based), whereas Mae Kon Khen and Mawker Thai villages are south (appendix). Most patients came from adjacent Myanmar (Burma). We compared the parasite clearance data with results from 119 patients studied in Pailin, western Cambodia (2007–10), where artemisinin resistance has been confirmed.² A subset of 30 parasite genotypes from Pailin was part of the genetic analysis. These studies were approved by the ethics review boards of the Faculty of Tropical Medicine, Mahidol University.

Falciparum malaria was diagnosed by microscopy of thick and thin peripheral blood smears stained with Giemsa. Parasite counts were read per 1000 red cells (thin film) or 500 white cells (thick film). Uncomplicated hyperparasitaemia was defined as 4% or more of red cells infected with malaria parasites without clinical evidence of severe malaria,¹⁹ and was the only criterion for inclusion in the analysis. Routine care was hospitalisation with a six hourly blood smear to monitor parasite clearance until smears were slide-negative. Treatment was with a 7 day regimen of oral artesunate (4 mg/kg initially, then 2 mg/kg once daily for 7 days), usually combined with either mefloquine (25 mg/kg in two divided doses), or doxycycline (4 mg/kg per day for 7 days) or clindamycin (5 mg/kg three times daily for 7 days) if mefloquine was contraindicated. In cases of clinical deterioration parenteral treatment was substituted. We monitored treatment until smears became slide-negative.

Procedures

DNA was extracted from admission blood spots by use of a two-step protocol to maximise DNA yield. Blood was eluted from six 3 mm diameter punches with the GenSolve kit (GenVault Corporation, Pleasanton, CA, USA), and DNA was then extracted with QIAamp 96 DNA blood kits (Qiagen, Valencia, CA, USA). Genotyping of 96 single nucleotide polymorphisms distributed across the *P. falciparum* genome was done with the Illumina Goldengate platform (Illumina Inc, San Diego, CA, USA) (appendix). We judged samples to be multiple-clone infections if more than five single nucleotide polymorphisms showed heterozygous base calls.

We measured the heritability of parasite clearance half-life to assess the part that parasite genetics plays in determination of this trait. Multilocus parasite genotypes infecting two or more patients were identified. Such parasite genotypes are equivalent to identical twins reared apart and can be used to measure heritability of parasite clearance (panel 1).

The geometric mean parasite clearance half-life in patients with artemisinin-resistant falciparum malaria in western Cambodia was 6.2 h (n=36, 95% CI 5.7–6.6),^{2,15} corresponding to a log_e normalised distribution with a mean of 1.8 (SD 0.22). Hyperparasitaemic patients on the northwestern border of Thailand in 2001 were used as a

reference artemisinin-sensitive population, with a mean log_e parasite clearance half-life of 0.95 (0.33). The hypothesis that the changes in parasite clearance half-life in western Thailand resulted from emergence versus importation of parasites with the same resistance phenotype prevalent in western Cambodia was tested.

Statistical analysis

We assessed parasite clearance using a standardised fitting method that separates the variable initial lag phase, during which parasite counts level off or rise, from the subsequent log-linear decline.¹² The slope of this phase was calculated and expressed as the parasite clearance half-life, which is the time taken for parasitaemia to fall by half during log-linear decline.²¹ Patients with parasite clearance curves showing a poor fit ($R^2 < 0.8$) to the log-linear model were excluded from the analysis.

We used Stata (version 11) to examine the association between parasite clearance half-life and the following covariates: age, sex, history of malaria, treatment regimen (artesunate with mefloquine vs artesunate with other partner drugs or artesunate alone), date of admission, duration of fever before presentation (<3 days vs ≥3 days), admission parasitaemia, haematocrit (<30% vs ≥30%), gametocytaemia, blood transfusion, and parenteral rescue therapy.

Univariate regression analysis of all listed covariates was done on log-transformed parasite clearance half-lives, followed by stepwise multivariate analysis (excluding parenteral rescue therapy). Variables that only significantly improved the final model (likelihood ratio test $p < 0.05$) were included (tables 1, 2).

To assess heritability, variance of parasite clearance was compared within and between clonally identical parasites recovered from more than two patients. Heritability (H^2) was estimated from the mean squares terms in ANOVA.^{15,21} H^2 was estimated for normalised parasite clearance and for residuals remaining after regression of clearance rates against patient and environmental factors.

We examined the hypothesis that changes in parasite clearance resulted from importation or emergence of parasites with the western Cambodian phenotype. The clearance rate distribution of a mixture of the western Cambodia and western Thailand populations was calculated as: $\pi \times \text{normal}([\log\{x\} - 1.8] / 0.22) + (1 - \pi) \times \text{normal}([\log\{x\} - 0.95] / 0.33)$, where π is the proportion of infections derived from the resistant population. For each year, we used the Kolmogorov–Smirnov test (50 tests for each year) to compare recorded distributions of log_e transformed half-lives with these theoretical distributions (for π between 0.01 and 0.50).

Role of the funding source

The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and final responsibility for the decision to submit for publication.

	N	Geometric mean parasite clearance half-life (95% CI)	Range	% change (95% CI)*	p value
(Continued from previous page)					
Study sites					
Mawker tai§	1035	2.945 (2.872–3.020)	0.805–12.545
Maela	439	2.940 (2.829–3.056)	1.028–9.385	–0.2 (–4.6 to 4.6)	0.95
Mae Khon Ken	148	2.958 (2.768–3.162)	1.205–8.636	0.5 (–6.4 to 7.9)	0.9
Wang Pha	1283	3.444 (3.367–3.523)	0.588–11.613	16.9 (13.1 to 21.0)	<0.0001

*% change refers to the change in parasite clearance half-life estimated from the regression model. †Patients not given artesunate and mefloquine received either artesunate with doxycycline or clindamycin, or artesunate alone for 7 days. ‡Day of admission was modelled as a continuous covariate; geometric mean was estimated at the start of the study (2001) and 10 years later (2010). Percentage changes are give for one year. §Mawker tai was used as a reference location for comparison with other sites.

Table 1: Effect of covariates on parasite clearance half-life of *Plasmodium falciparum* examined by univariate analysis

	% change in geometric mean parasite clearance half-life	95% CI	p value
Study centre*			
Maela	5.64	4.34 to 6.95	<0.0001
Wang Pha	2.60	1.11 to 4.11	0.00059
Mae Khon Khen	1.65	–6.09 to 10.02	0.68
Mawker Thai	1.68	0.72 to 2.65	0.00062
Presence of gametocytaemia on admission	5.55	0.57 to 10.78	0.029
Haematocrit <30% on admission	7.33	3.10 to 11.73	0.00056
Fever ≥3 days	7.37	4.17 to 10.67	<0.0001

*Change per year estimated within each study location.

Table 2: Admission variables associated with parasite clearance half-life of *Plasmodium falciparum* in multivariate regression analysis




Figure 1: Parasite clearance half-life of *Plasmodium falciparum* on the Thailand–Myanmar border over 10 years We plotted untransformed parasite clearance half-lives over time for all malaria infections with a good fit to a linear model ($R^2 > 0.8$). Data from western Cambodia gathered between June, 2007, and November, 2010, are shown for comparison, compressed as if they had been obtained in a single year. The dotted red line shows a threshold value of 6.2 h, used to differentiate between fast-clearing and slow-clearing infections. The dotted blue boxes show the periods for which bloodspots were available. These two time windows form the basis of the genetic analysis.




Figure 2: Change in parasite clearance half-life of *Plasmodium falciparum* 2001–10

(A) Geometric means of parasite clearance half-life in patients with hyperparasitaemia on the Thailand–Myanmar border. *Subset of infections treated with artesunate monotherapy (ART) for more than 48 h, for which 48 h clearance rates and parasite clearance half-lives were calculated. Error bars are 95% CIs and above them is the number of patients. (B) Proportion of patients with very slow clearance (parasite clearance half-life ≥ 6.2 h). Error bars are binomial 95% CIs. Colour scheme is as per A.

Results

Between July, 2001, and December, 2010, 3202 hyperparasitaemic patients were treated. Most patients were younger than 15 years (appendix). Most patients (2403) were given oral artesunate and divided doses of mefloquine. The remaining patients were given artesunate monotherapy

(321 patients), artesunate in combination with either doxycycline (382 patients) or clindamycin (71 patients), or other combinations (25 patients). Patients who got blood transfusions within 24 hours of admission, or an incomplete course of or more than one parenteral dose of artesunate were excluded from the analysis. 2855 patients (1268 in Wang Pha, 975 in Mawker Thai, 467 in Maela, and 145 in Mae Khon Ken) remained eligible, of whom 1778 (62%) were men or boys. In 1759 of 2855 patients, artesunate monotherapy was given, or else the partner drug (mefloquine, doxycycline, or clindamycin) was given more than 48 h from the start of artesunate treatment. All patients survived, confirming the effectiveness of oral artesunate in uncomplicated hyperparasitaemia.¹⁸

Between 2001 and 2010, the median age of hyperparasitaemic patients increased slightly but significantly from 11 years to 15 years ($p < 0.0001$). The proportion of patients developing severe malaria did not increase over time, nor did the ratio of severe to uncomplicated falciparum malaria cases, malaria mortality, nor the proportion of patients developing anaemia. We noted a significant increase in the proportion of patients with gametocytaemia on admission ($p < 0.0001$; 7.5×10^{-6} test for trend).

Parasite clearance half-life lengthened from a geometric mean of 2.6 h (95% CI 2.5–2.7) in 2001, to 3.7 h (3.6–3.8) in 2010 ($p < 0.0001$), compared with 5.5 h (5.2–5.9) in the 116 patients from western Cambodia between 2007 and 2010 (clearance data from three patients fitted poorly to the linear model [$R^2 < 0.8$] and were thus excluded) (figures 1, 2A, table 1). We used a stringent threshold of a parasite clearance half-life of more than 6.2 h to categorise infections with slow or fast parasite clearance; the proportion of patients at our study centres with slow clearance rose from 0.6% in 2001, to 20% in 2010, compared with 42% of patients in western Cambodia in 2010 (figure 2B). Parasite clearance rates in patients given artesunate monotherapy or given artesunate alone for more than 48 h ($n=1759$) before receiving partner drugs were similar to those in patients who were given combination treatments immediately, suggesting that increasing resistance to the partner drug cannot explain the temporal changes reported.

No relation existed between parasite clearance half-life and age ($p=0.439$) or starting parasitaemia ($p=0.598$) in patients given artesunate monotherapy or given artesunate alone for more than 48 h before receiving partner drugs, nor in all patients ($p=0.124$ and $p=0.569$, respectively). The variable most strongly associated with increases in parasite clearance half-life was the date of patient admission (appendix). This trend was strongly significant in all clinics sampled except Mae Khon Ken, Thailand (table 2; appendix). Only 7.4% of the variation in half-life could be explained by other admission variables. Location had a significant effect on parasite clearance; infections in northern locations (ie, Maela and Wang Pha) had slower clearance than those sampled in the south (ie, Mawker Thai and Mae Khon Ken) (appendix; table 2).

Of 96 single nucleotide polymorphisms assessed, 93 gave robust genotype data. Of the 1583 infections genotyped, 1029 were single-clone infections (appendix). From these, 148 unique 93-locus parasite genotypes were identified, each infecting between two and 13 patients (29 from 2001 to 2004, and 119 from 2007 to 2010) (appendix). Patients harbouring parasites with the same 93-locus genotype had similar parasite clearance half-lives (figure 3), showing the important part played by parasite genotype. Between 2001 and 2004, parasite genotype had a significant effect on parasite clearance half-life ($p=0.0166$), even after adjusting for significant covariates ($p=0.01$). Two of the three patients with the longest parasite clearance half-lives recorded before 2004 had the same 93-locus genotype (figure 3). From 2007 to 2010, parasite genotype had a much stronger effect on parasite clearance half-life ($p<0.0001$) than it had between 2001 and 2004, and remained highly significant after adjusting for other covariates ($F=5.219$, $df=118$, $p<0.0001$). Mean H^2 increased from 0.30 (SD 0.14) in 2001–04, to 0.66 (0.04) in 2007–10. After adjustment for the effects of covariates, H^2 rose from 0.32 (0.14) between 2001–04, to 0.58 (0.05) in 2007–10 (appendix). The increase in H^2 was tested by permutation and was significant both before ($p<0.01$) and after ($p=0.04$) adjustment for covariates (appendix).

To investigate whether the increase in H^2 was driven by alleles conferring slow parasite clearance, we removed 30% of the slowest clearing infections from the 2007–10 dataset, which caused H^2 to decrease from 0.66 (SD 0.04) to 0.17 (0.07). Removal of 30% of the fastest clearing infections increased H^2 to 0.70 (0.05), whereas random removal of 30% of infections did not alter H^2 (mean H^2 from 100 randomisations 0.67 (0.03); range 0.56–0.74). These in-silico experiments show that high H^2 is driven by parasite genes that determine slow parasite clearance.

Admixture of parasites with the Cambodian phenotype could explain the parasite clearance distributions in 2001–02, and 2009–10, but not those between 2003 and 2008 ($p<0.01$). This finding suggests that the gradual increases in parasite clearance half-life are unlikely to be explained by a single-step process of importation or de-novo selection of a parasite population with the same characteristics as the resistant parasites prevalent in western Cambodia.

None of the 93-locus genotypes was common to patients from the Thailand–Myanmar border and western Cambodia. Pairwise allele sharing (ps) between the 25 slowest and 25 fastest clearing parasites from the Thailand–Myanmar border was compared with 30 slow-clearing parasites from western Cambodia. Cambodian parasites were more closely related ($ps=0.453$) to slow-clearing parasites than to fast-clearing parasites ($ps=0.450$) from the Thailand–Myanmar border. However, permutation tests show that this difference is not significant ($p=0.137$, 10000 permutations).




Figure 3: Effect of parasite genotype on parasite clearance rates

Clearance half-lives in patients infected with parasites bearing identical 93-locus genotypes. Red dotted line marks the 6.2 h threshold used to categorise slow-clearing parasites. The arrows show slow clearance parasite genotypes gathered in November, 2003. *Ranked by mean parasite clearance half-life.

Discussion

This large prospective series of patients with hyperparasitaemia during 10 years provides clear evidence that parasite clearance responses after artesunate treatment are slowing on the northwestern border of Thailand (panel 2). The rate of decline is consistent with theoretical expectations and empirical data for the spread of resistance loci through a parasite population under drug selection.^{27–29} If the rate of decline continues then parasite clearance half-lives on the Thailand–Myanmar border will be similar to those in western Cambodia within 2–6 years.

Parasite clearance after treatment with artemisinin derivatives is determined mainly by drug effectiveness, although host immunity and the partner drug can also contribute.¹² The frequency of malaria and the proportion of multiple-clone infections (appendix) in the study area in northwestern Thailand have fallen over the past 10 years; thus immunity to malaria has probably also declined. Because patients with hyperparasitaemia are unable to control their infection, changes in immunity are unlikely to have contributed substantially to the slowing of parasite clearance. The absence of any relation with age in this study provides strong support for this contention.

Similarly, although previous malaria exposure has a weak effect on parasite clearance half-life (table 1), this finding cannot explain the temporal trends noted (appendix). The artemisinin combination treatment partner drug mefloquine has been used in this region for more than 25 years, and resistance developed rapidly after initial deployment. The proportion of *P. falciparum* isolates with increased *pfmdr1* copy numbers (the main determinant of

Panel 2: Research in context

Systematic review

We searched for trials on artemisinin resistance on PubMed using the term “resistance” in combination with “artemisinin”, “artesunate”, or “artemether”, and confined the search to clinical studies in which resistance had been suspected or confirmed on the basis of assessment of parasite clearance. Additionally, we searched for all clinical trials or assessments of artemisinin combination treatments. We identified 101 references. The only area where slow parasite clearance has been unambiguously shown previously is western Cambodia (four studies reporting parasite clearance).^{1,2,22–24} Artemisinin resistance has been suspected because of diminishing treatment responses to artemisinin combination therapies on the western border of Thailand^{16,25} and changes in parasite clearance rates on the Kenyan coast.²⁶

Interpretation

Although artemisinin resistance has been suspected outside western Cambodia, this study provides the first unequivocal proof that resistance has emerged or spread westward. It confirms (with a large sample size) findings showing that this phenotype is explained mainly by a heritable genetic trait in the parasite population. The research suggests a potential transmission advantage associated with resistance to artesunate through increased gametocyte carriage on admission. These findings suggest that regional artemisinin resistance-containment strategies should be reviewed. Increasing the availability of artemisinin combination therapies in southeast Asia will reduce the incidence of malaria but provides a selection pressure driving artemisinin resistance. The development of strategies to reduce the selection and spread of artemisinin-resistant *Plasmodium falciparum* while continuing to drive down the incidence of malaria is of the highest priority.

mefloquine resistance) has been increasing over the past decade.¹⁶ However, the temporal changes in parasite clearance half-lives for patients given artesunate monotherapy for more than 48 h before administration of partner drugs were closely related to those reported in the full dataset, showing that resistance to the partner drug does not contribute substantially to the changes recorded (figure 2).

The genotyping data provide compelling evidence that parasite genetic factors explain the fall in parasite clearance rates. In this low transmission setting, different patients are often infected with genetically very similar parasites, allowing assessment of the contribution of genetic factors to in-vivo phenotypes.^{15,30} After adjustment for covariates, the heritability of parasite clearance increased during the study period, from 32% between 2001 and 2004, to 58% between 2007 and 2010, which is consistent with an increasing prevalence of alleles determining slow parasite clearance.²⁰ The increased contribution of genetics was confined largely to the parasites with the slowest clearance rates. The high heritability of slow parasite clearance suggests that this trait will spread rapidly under continued selection.

This study shows the importance of longitudinal detailed monitoring to detect the early emergence of antimalarial drug resistance. Hyperparasitaemic patients provide important information on temporal trends in artemisinin susceptibility because confounding by immunity and partner drug effects is minimised and clearance rates can be assessed accurately (>10 sequential parasite counts for individual patients in this analysis). The slope, and thus

the derived parasite clearance half-life of the exponential decline (ignoring the variable lag phase) is judged the key pharmacodynamic determinant of the artemisinins.²¹ No evidence suggests saturation or density dependence in parasite clearance rates. Thus parasite clearances in patients with hyperparasitaemia can be compared with data from patients with lower parasitaemias, notably the artemisinin-resistant *P falciparum* infections in western Cambodia.

This study cannot establish whether resistance alleles present in western Cambodia and northwestern Thailand have a common origin. Parasites with identical 93-locus genotypes were not recorded at the two sites, nor were slow clearing parasites from northwestern Thailand more closely related to Cambodian parasites than were fast clearing parasites from western Thailand. The evolution of artemisinin resistance will possibly be understood when the genetic determinants of parasite clearance rates have been identified.^{7,31}

Parasite clearance rates in northwestern Thailand are continuously distributed. Modelling of the changes in parasite clearance over time did not support selection of a single artemisinin-resistant subpopulation with the same clearance phenotype as in Cambodia—ie, a one-step process. Together with the finding that clonally identical parasites with slow parasite clearance were reported in different patients in northwestern Thailand 8 years ago, this result argues against recent importation of Cambodian parasites as the explanation for the reduction in parasite clearance.

The artesunate–mefloquine combination has been the first-line treatment for falciparum malaria on the western border of Thailand since 1994. Artesunate was added to a failing mefloquine regimen, and the high effectiveness of the combination (>90% day 42 cure rates) has been sustained since then, although evidence suggests that effectiveness is decreasing,¹⁶ with a day 42 cure rate in 86 patients in 2010 of 88·9% (95% CI 77·8–94·7). Declining artemisinin effectiveness will have an adverse effect on the treatment of uncomplicated falciparum malaria by slowing therapeutic responses and increasing treatment failure rates, and will reduce the remarkable life-saving effectiveness of artesunate in the treatment of severe malaria and hyperparasitaemic patients. The degree to which current rates of resistance compromise these benefits has not been established, although the proportion of patients developing severe malaria did not increase concomitantly with the decline in artesunate effectiveness in this location. No patient died in this series, whereas in the past the mortality rate in patients given quinine for uncomplicated hyperparasitaemia was 3%.

A potential radical approach to containment of artemisinin resistance is to try to eliminate *P falciparum* malaria from western Cambodia, but would this strategy be justified if resistance has already spread or emerged elsewhere?²⁷ Genetically determined resistance to artemisinins is now prevalent on the Thailand–Myanmar border, contiguous with a malaria endemic area in which a large

burden of uncontrolled disease exists, so containment efforts will need to be expanded and surveillance and control strategies re-examined. Whether the fitness and transmissibility of the resistant parasites in the two locations are similar cannot be established yet, and thus elimination of falciparum malaria in western Cambodia might still be beneficial through prevention of the spread of higher degrees of resistance.

Identification of a molecular marker will be crucial to monitor the distribution and spread of resistance and to understand the evolution of this trait and the mechanism of action of artemisinin. The large numbers of patients infected with malaria, high heritability, and the broad range of parasite clearance half-lives make the Thailand–Myanmar border region ideal for powerful association studies.³² Clinical studies are needed urgently to map further spread and to establish the effect of different degrees of artemisinin resistance on treatment effectiveness and transmissibility.

Contributors

TJCA, StN, EAA, FN, and NJW contributed to study design. EAA, RM, AD, APP, CIM, KML, and FN collected clinical data. StN, ShN, and SA-S did molecular work. StN, KS, EAA, TJCA, and FN analysed the data. StN, TJCA, EAA, FN, PS, NPJD, and NJW wrote the manuscript. APP and SN contributed equally to this work. TJCA and FN also contributed equally.

Conflicts of interest

NJW is co-chairman of the WHO antimalarial treatment guidelines committee. All other authors declare that they have no conflicts of interest.

Acknowledgments

The clinical study was done as part of the Wellcome Trust–Mahidol University–Oxford Tropical Medicine Research Programme supported by the Wellcome Trust. Molecular work was funded by National Institutes of Health grant R01 AI048071 awarded to TJCA and done in facilities constructed with support from Research Facilities Improvement Programme (grant number C06 RR013556) from the National Center for Research Resources, National Institutes of Health. We are grateful to all the patients and staff who contributed to data collection, to Verena Carrara for providing additional data and the maps, to Ian Cheeseman, to Christine Luxemburger, and to Ric Price. The genetic analysis was stimulated by discussions with Carol Sibley and Philippe Guerin (Worldwide Antimalarial Resistance Network).

References

- Noedl H, Se Y, Schaecker K, et al. Evidence of artemisinin-resistant malaria in western Cambodia. *N Engl J Med* 2008; **359**: 2619–20.
- Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med* 2009; **361**: 455–67.
- WHO. Global malaria control and elimination: report of a meeting on containment of artemisinin tolerance. Geneva: World Health Organization, 2009.
- Dondorp AM, Yeung S, White L, et al. Artemisinin resistance: current status and scenarios for containment. *Nat Rev Microbiol* 2010; **8**: 272–80.
- Verdrager J. Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia. *J Trop Med Hyg* 1986; **89**: 277–89.
- Payne D. Spread of chloroquine resistance in *Plasmodium falciparum*. *Parasitol Today* 1987; **3**: 241–46.
- White NJ. Artemisinin resistance—the clock is ticking. *Lancet* 2010; **376**: 2051–52.
- Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. *Science* 2004; **305**: 1124.
- Anderson TJ, Roper C. The origins and spread of antimalarial drug resistance: lessons for policy makers. *Acta Trop* 2005; **94**: 269–80.
- Maude RJ, Pontavornpinyo W, Saralamba S, et al. The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. *Malar J* 2009; **8**: 31.
- WHO. Global plan for artemisinin resistance containment (GPARC). Geneva: World Health Organization, 2011.
- Stepniewska K, Ashley E, Lee SJ, et al. In vivo parasitological measures of artemisinin susceptibility. *J Infect Dis* 2011; **201**: 570–79.
- White NJ, Qinghaosu (artemisinin): the price of success. *Science* 2008; **320**: 330–34.
- Saralamba S, Pan-Ngum W, Maude RJ, et al. Intrahost modeling of artemisinin resistance in *Plasmodium falciparum*. *Proc Natl Acad Sci USA* 2011; **108**: 397–402.
- Anderson TJ, Nair S, Nkhoma S, et al. High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. *J Infect Dis* 2010; **201**: 1326–30.
- Carrara VI, Zwang J, Ashley EA, et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. *PLoS One* 2009; **4**: e4551.
- Luxemburger C, Ricci F, Nosten F, Raimond D, Bathet S, White NJ. The epidemiology of severe malaria in an area of low transmission in Thailand. *Trans R Soc Trop Med Hyg* 1997; **91**: 256–62.
- Luxemburger C, Nosten F, Raimond SD, Chongsuphajaisiddhi T, White NJ. Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria. *Am J Trop Med Hyg* 1995; **53**: 522–25.
- WHO. Severe falciparum malaria. *Trans R Soc Trop Med Hyg* 2000; **94** (suppl 1): 1–90.
- Visscher PM, Hill WG, Wray NR. Heritability in the genomics era—concepts and misconceptions. *Nat Rev Genet* 2008; **9**: 255–66.
- Flegg JA, Guerin P, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. *Malar J* 2011; **10**: 339.
- Bethell D, Se Y, Lon C, et al. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. *PLoS One* 2011; **6**: e19283.
- Song J, Socheat D, Tan B, et al. Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia–Thailand border area. *Malar J* 2011; **10**: 231.
- Noedl H, Se Y, Sriwichai S, et al. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. *Clin Infect Dis* 2010; **51**: e82–89.
- Na-Bangchang K, Ruengweeraayut R, Mahamad P, et al. Declining efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along the Thai–Myanmar border. *Malar J* 2010; **9**: 273.
- Borrmann S, Sasi P, Mwai L, et al. Declining responsiveness of *Plasmodium falciparum* infections to artemisinin-based combination treatments on the Kenyan coast. *PLoS One* 2011; **6**: e26005.
- Antao T, Hastings IM. Environmental, pharmacological and genetic influences on the spread of drug-resistant malaria. *Proc Biol Sci* 2011; **278**: 1705–12.
- Roper C, Pearce R, Bredenkamp B, et al. Antifolate antimalarial resistance in southeast Africa: a population-based analysis. *Lancet* 2003; **361**: 1174–81.
- Alifrangis M, Lusingu JP, Mmbando B, et al. Five-year surveillance of molecular markers of *Plasmodium falciparum* antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the *P falciparum* dihydropteroate synthase gene. *Am J Trop Med Hyg* 2009; **80**: 523–27.
- Anderson TJ, Williams JT, Nair S, et al. Inferred relatedness and heritability in malaria parasites. *Proc Bio Sci* 2010; **277**: 2531–40.
- Nair S, Nash D, Sudimack D, et al. Recurrent gene amplification and soft selective sweeps during evolution of multidrug resistance in malaria parasites. *Mol Biol Evol* 2007; **24**: 562–73.
- Cheeseman I, Miller BA, Nair S, et al. A major genome region underlying artemisinin resistance in malaria. *Science* 2012; published online April 5. DOI:10.1126/science.1215966.

THE LANCET

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Pyae Phyo A, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. *Lancet* 2012; published online April 5. DOI:10.1016/S0140-6736(12)60484-X.


APPENDIX MATERIAL

Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study

Aung Pyae Phyo, Standwell Nkhoma, Kasia Stepniowska, Elizabeth A Ashley, Shalini Nair, Rose McGready, Carit ler Moo, Salma Al-Saai, Arjen Dondorp, Khin Maung Lwin, Pratap Singhasivanon, Nicholas P J Day, Nicholas J White, Tim J C Anderson, François Nosten

Contents:

- Appendix 1. Geographical variation in clearance rate
- Appendix 2. Single nucleotide polymorphism genotyping
- Appendix 3. Age structure of patient population
- Appendix 4. Multiple regression analysis of clearance rate, stratified by location.
- Appendix 5. Genotyping data for one SNP.
- Appendix 6. Sampling breakdown for epidemiology and genetic analyses.
- Appendix 7. Genetic relatedness among parasites.
- Appendix 8. Change in heritability of clearance rates on the Thai-Myanmar border.
- Appendix 9. Permutation-based comparison of heritability in 2001-4 and 2007-10.



Appendix 1. Geographical variation in $t_{1/2} P$. The section of the Thai-Myanmar border containing the four study clinics is shown, with bar charts showing changes in the proportions of slow clearing parasites ($t_{1/2} P \geq 6.2$ hrs) from 2001-10. Years in which no patients were treated are marked “nd”. There is a sharp rise in proportions of slow clearing parasites in clinics north of Maesot between 2008-10.

Appendix 2: SNPs genotyping. SNPs are named by chromosome and position in genome version 6.2. Alternate bases at the SNP are shown in square brackets, with 50-60bp flanking sequence on either side. SNPs marked with an asterisk (*) are on the reverse DNA strand. These SNPs were chosen, because they are highly polymorphic in parasites from the Thai-Myanmar border, robust to genotype, and distributed accross all 14 chromosomes. These genome wide SNPs were used to accurately identify parasites that are identical (or very similar) over the whole genome, rather than because they are predicted to play a role in determining clearance rate. The SNPs are situated in coding regions in both synonymous and non-synonymous sites. SNP genotyping was carried out according to the Illumina BeadXpress instructions, using ~100ng template DNA. Excel version of table available on request.

Locus_Name	Sequence	Chr	Pos	Minor allele	Minor allele freq.
*MAL01-354427	TACTAGGTTGGTTTTATATAGAAGATTGCTATGTTATATAACATCAGATTCATTTA[T/C]ATTATTATTTTGTCTTCGTGTTATGGTATCTTTTATTATTAGAAATATTATTATAATC	1	354427	A	0.43
MAL01-539149	TCCTCTTTTCAGTGGATGCCATTTGTTTTTAAATGTGTTAAATCATTGTGAATTTTTAT[A/G]ACTTTTAATAAATGTACGCATAAAATCTTTATATTCATATTATTTTAAATATTTCTTTACT	1	539149	G	0.31
MAL02-217337	TTTGTTTAGAGCATCTTTATTTTGGAAAAACATCCCTCCTTCAAAGGATCATACGATT[C/A/T]TTTCCTTTCATACAAAAAATAAAAAAATAAATAAATAATATACACATATATATAAA	2	217337	T	0.29
MAL02-322398	TTACACATAACAGAAAAACATTCATTTTGAACCCCTTCAGTTTGGTTAAACAAATACCAGG[A/G]GATGTTTATCTTTACATTCATTCCAATGGAGTTCACAAAATTTAATACATCCTTCATGT	2	322398	G	0.26
*MAL02-660994	TTTTTAAATAATATGTCCAAATGTGTTTTATACCAAAAAAAGAAGCATATCAAGAATCA[T/C]CAGAACAAAATCCCATGTCTTTATAAATCATAAAAATGAAGACAAATGAAAAATGTCATA	2	660994	G	0.17
*MAL03-249686	ATACAAAATAAAGAGGAAGATATATAAATATGTTAATGAACACAAAA[T/C]AGTGATGTGCAAAAAAGAAAAAGAGTTGAAAAACAATAAATGAAGTTTT	3	249686	G	0.49
MAL03-439621	AATTTATTATTATTAATATAACAAAGAAATGTGGACATAAAAAAA[A/G]AAAGCGAGTTTGTGAAAAGCAATATGCTCTAATAATAGGATACCATCTAA	3	439621	G	0.25
*MAL03-704420	ATTAAATGTGTTTTTAAATTTTGAACAAATTTTTTCAACATCTTCATTTGC[T/C]CGTGTTAATGTTATGATTTTCATTGGATTTTATTAATAAATCGTTTAA	3	704420	G	0.17
MAL03-748204	CAATATGATAGAACTGAAGAAATTTCAATATGGAGATATTATTCATTTTTAT[T/C]TATGGAGAAGATGGTATGGCAGGTGAATATATAGAAGATCAAAATATAGA	3	748204	A	0.44
MAL03-822470	AAATATGTTAAATAATAAATAATAATAATAACTCTTTTTATACATGAGAGATAT[T/C]CAGAATTGACAGACATTTGAAGAAAATATATCAAGTAAAAAATAAAAAAATAAATTTATAG	3	822470	A	0.39
*MAL04-268436	TCTCATATTATTATTCCTATTTCATAAGTAATAAACCTTTGTGTATTTTGGAAACACAT[T/C]TTTATGTCCTCAAGATATACCACATTTTGGACATTATTATTATATCAATTATTATCATT	4	268436	A	0.29
MAL04-307321	GATGATCATATATGGAATATAATTTAATGGGAATCAAAATTAATAATAATCAAAAATAT[A/G]CACCACATCTTGATATACCAACAACATTTTATGCAGATATACATAGACCAATCATCTTC	4	307321	A	0.16
MAL04-393114	ATTGATAACCCAGAGTAACGAACATTTCAACATGAATAATATTGAAAGTAAGAACAT[A/C]TTGATGGTATTCGTAAATATGAACCATTTTCAAGAGTGTGATTTCTCAGATATGACAACAA	4	393114	A	0.45
MAL04-443828	CTTGCTATAACTATTAGATTGTGAGATGAAATTATTGATAAGTCTTTTAA[A/G]GAACCCACAGCAGCTTATTAAAGCGTGCCGTAAATGAACACCTTAATAACAT	4	443828	G	0.28
MAL04-469608	CCATGATTTTTCGGCAACGGCGCTTCCGCTACTCTCCGCTATATC[A/G]ACTACAAGGCTTTGAAAAACAAGTAAAAAGAAATATATAAATGAAT	4	469608	G	0.44
MAL04-494108	AAATAAAATTTATAAACATGTCTACAAACATAAATGAAGGACATCGAAAGTGCATAATGATTTTACATACAAAAACAATATAATATGTTATGTAGTAAAGTTGGTGCAATCAGGTTCCCTCC	4	494108	T	0.35
*MAL04-809686	ATATCAAAACATCAACAAGTATTATCTTCAGTATGATCAAAATAAAGAAACCTCTGGAAT[A/G]AACATCAAAATCACAAGAAAGATTTCGATGTGCACAAATGTGATACAAGCAAAATGA	4	809686	nd	nd
*MAL04-933828	GGATAACTCTAAATATTGTGGAATGTGGGAATGGAGACAAGAAAGCATGATTATAATATC[T/G]CGTCAAAAAAGAGAGGATGAGAAATTTAGTGTAGTAAATGCTTTTATGATGATGAGT	4	933828	C	0.35
MAL04-994352	ATTTCTCTCATTTTTATTAATATCAACATATATTTTAAATGATGGATTTTTTATTATT[A/T]TTTTTTTCTTTATATTTTCTCATTCACGTTCTCTCAATTTCAATAACATTTTCTCTCTTT	4	994352	T	0.42
MAL04-1037032	CTTAAGTAAATTTTTAATGATAGAAATATCTCTAGTGAATATTATTATCGGAAAAAGA[A/G]CATGTAATAAATGAGAATTTAAAAAGAGATTTTACCATTGGATTTTGGAAATTCATCATGCA	4	1037032	A	0.44
MAL04-1101563	TTTTTTTAAATTTTAAATCAAGTGGATCATGATGTTGTATGAGAGAAAGATTTTTCGAAT[C/A/G]TGCAATATAAATGTTTTCAGGAGAAAGGTTTTTCAAGTATGTTTATCTCGGACAAAAAATA	4	1101563	C	0.29
MAL04-1140617	GATAAAAATTTTCAAGGAATATATTAAATATGAGAAATCTGAAGATATATTGAAATG[A/G]TTAAAGGGTGAAGTCTGTAATAATTAGAAATTAATATGTCGTAATGAATGTAATGTAATCC	4	1140617	G	0.46
MAL05-118209	CTTCTCTTTTCTAACCATATTACATAGAAATTCATATCTCTTAACTTTTTATTTAT[A/G]TTTTGTCCCTTCCATTTTCTCTTCCATTTTCAATGATTTTTCTTTTATATGCTT	5	118209	G	0.28
*MAL05-385372	AAAAAATTTATCGATGATCTAAAGAGATCTTGAAGAACTTTTGGTGATAG[T/C]GATGAATTTAAAAAATTAGAACATGAATATGATCATATTAATATAAACGA	5	385372	A	0.11
MAL05-720978	TTATCTCTGTCATCATATATAAAAAATATTTTGGTCATCTAAACCCCA[A/G]AGTCTATTTTTTCGATCAAGGCTGAGAGATTTTAACTTAAAAATACCATA	5	720978	A	0.31
*MAL06-154776	TCCAACACATCTCTTTTTTCTCATGTTCAATATTTTCTTACGATGATCTGGCAGCAAT[T/C]TAAATCGTTTAAATATTTTCTCTTTTAACTCTCTCATCATTAATTTATCAACACATTAGCAC	6	154776	A	0.30
MAL06-410691	ATACATGTATAATAAAAAATGTTGGTGTCATCTCTCAACTAAAAAATGTTGAAGAATTTGTC[A/G]AAGTTGATTTGTTTAAATAAATATGGGAATAAAATTTTCAATATTTATATATTTAAA	6	410691	A	0.27
*MAL06-573730	AGAAAAACGCTCAAGGAATTTTACACTCAGCTTAGATGTGAAGCCATC[T/C]TATCCTCTTATAATAATCCAGAAAAAGAAATAATACATGTATGCAAAAAATAT	6	573730	A	0.20
*MAL06-593821	TCATCTTTAAATCTTTTATTTTCTCAAAACATTTGTGCATCTCTTAAA[T/C]CCATAAGATTAAGATTAACCCATAACACACAATTTATTATTAAAAAAGA	6	593821	A	0.22
MAL06-937750	ATAGGTGTCCTCAATACCTTATAGAGAGGATTTGTATATGATGCATAGGAAT[A/G]CCGCCAACACATCTCTCTTATTTTATGTTTCAAAATATAAGAACAAAT	6	937750	A	0.39
MAL06-1184507	AAAAAATAAAAGACAAATTAATGATGAATATTATGTGTGATCATCAAAATTTGTCAC[A/G]TGAAAAATATAGAGACAACATCTGAGAAAAAAGAAAAAGAAATTTTCAAGAAAA	6	1184507	G	0.46
MAL06-1206499	CGTAGTGAAGTGAATAGATGATATAGATGAATTAGATGAAGAAGAAATATGATTGGACG[A/G]AGCATGTATAATAATTAAAGCCTACCACCTTATTATTACCTGGGTGGGAGGAAGTACAT	6	1206499	A	0.12
MAL07-476303	CTGTGCGGCACAGGAGGAAGATCCCCCTCAAAATCTTTTGGCTCTCATGATTTTTTCAT[C/G]TGCCCTGTTGAATATTCATTTTTTTCATTAATTTCCCTCTGAGAGGTTATATAATTACTA	7	476303	G	0.30
MAL07-511352	CATTATTTTGTATTTTAAATTTTAAATTTATTTACTTACCAATTTGTGAAATATGATATGA[A/G]GCCAAATTAATTTTCAACTATTTCATGTTTCAACAAAATAAGCACAGGTATATATAAGAG	7	511352	A	0.42
*MAL07-543849	TTTTATTTTTTTTTTCTCCATATCTATGTAGAAATCATTTTTATAATATCTCAACGCAT[T/C]TGTTTTTTATCATAACTGGAATCTTTATTCATTTTCATTTTGTGCATTTGTGAACAGGT	7	543849	G	0.31
*MAL07-672051	CATTTTCTTAATGTTCATATGTATAATTTTTCAGAACGAAATGGGACATAAAAAATATAC[A/C]CCGATAGATGGATATAATATGTTTCTTCAAGAGAAACGATATGAATATGTAATGGTA	7	672051	nd	nd
MAL07-759749	AAGTATCGAAAGGAAGATTAAAGAGAAACACAGAAATATAGAAGATGAAGACTCAGAGGA[A/G]AGTCAGCAAGATGGAAGGAGAGAAAAAGGCAAGCAGAGATATAATATAAGAAAGA	7	759749	G	0.33
*MAL07-1122023	ATGATATATTTTATTTATGTTATTAATATATATCATATTGTTTAAAGGAAGAGAAATATTTT[A/G]AATTTGTTAAAAAAGAGATAAAAAATGGATATTATACAATGGCTTCATTATGTTTGTGAA	7	1122023	A	0.44
*MAL07-1289206	TTTAATAACTGTGTTTTTTTTTAAATTTATTTAGATTTGTGCTTTTTCTCATATGAATTTATGCAAT[T/C]GTCTTAAAGAGAAATATCAAAATATTTTGTGGCCATGCTCACACTTTGTGATATACA	7	1289206	G	0.15
*MAL07-1311707	TTAATAAATAAATAATTTTAAACATGATGGAGTTGGTAATATAAATATGATATGATGAAGG[T/C]TTAATAAAAAAGAGAGCAAAATATTTTACACACCCCTTGATGGAACATAAAAATATAA	7	1311707	A	0.08
MAL07-1323949	GGTTGTGAAGGACGATGAATAAAAAATAAAAATTTTAGATCATTTAGAAAAAATGAAAC[A/C]TGTAAGATGATTTTGTATGTAATGAACATAAAATCGTTAATTGAAATTTATTCAGAAAAAT	7	1323949	A	0.31
MAL08-417613	AAGTATCAAACTGCCATAAATAATATGCAATGGTTTCTTCCGATGTGATCATCGATTTGCAAT[A/G]TAGGCAGGCATACATACATCGTTTAAATATCATATATCTTCTGGAATTTTCAATG	8	417613	G	0.41
MAL08-477431	AAATATAAATGTACCACAACACATGATAAACAAAGGTGAAGGAAATTTTCAAACT[A/T]TTTGTTTAATGAATATATGAAAAAGAGAAAAAGAAAGCAAAATGAAGAAATATTTTA	8	477431	T	0.43
*MAL08-502163	TTTTAATTTTACACTTATGCTCTCTTCTGTTATGAGTTAAAAATTCGCTTTCTTTAC[T/C]TCGCAAGAATATATCTGTGGAACGATTAATATACAAAAAGAAATAGGATCTACATCTATT	8	502163	G	0.12
MAL08-1057901	AGAATCTCTTTATGATGGGTTTCTGTATAGAAGAAATAGTGTAAACAGAAATGAGGACAC[A/C]TATTTAATAACATTTGAATTTGTGTTATTTCTATATTTCTTATAGTCAGAACGAAGCTTTAG	8	1057901	C	0.34
MAL08-1101130	CATGACACACAATTTAAAAAAAATATTAGTACCCAGACATGTCATACGCCG[A/G]CAGGATTTACAAATGAAGAAATGATAGCAAAAGATGACAAATTAATGA	8	1101130	G	0.21
MAL08-1292195	TTTTAGAGATTTCTGTAATTTATTTATCAAGTCTTATCATATGTAAGAGAGAGAGGAGG[A/G]GTCTATGTTGATGTCATGTTTAAATCAGAAATTTTTTGTACCTCTCAAGTATTTTCATA	8	1292195	G	0.29
MAL08-1311981	AAATCTACTCTGAAATACITAAAAAGATATGGGAAAGTATATAGATAAAAAATTTACCA[C/G]GCTTGATGGAGAAACAACAAAAATACCTGTGTGTAGAGTTGCACATGATTATGAAAAGG	8	1311981	C	0.37
*MAL09-492618	TATATATAACACTATTCAAAATTTGTCGAATTTGATTATAGAAGAGGAATTTGCTAAGAAATAT[T/C]TATCTTACAGGAGGTTTCGAGTATTATAAGAGGCTTTAGACAAAGATTGGGAATGAACCT	9	492618	G	0.24
MAL09-631767	AGATCTTTCTTTATGACCAATGCATATGATTTAAACACGCTTTTCTTTTATCAACAGTT[T/C]TGCTTTTTTACACCTCTCACTTTTTTGGATATATAGTGGCAATATAGGTTCTGTTTATG	9	631767	A	0.22
MAL09-692487	TTTTTATTTATCTATTATAATTTCTTGTAATTTGTGAAATGGTATATGGGCATATA[A/C]ACATTTTATAATTTTCCGAGATCTTTACATTAACCTTTTCTATACAAAATTTCAACGGC	9	692487	C	0.28
MAL09-771381	AAACGACACAAGTCAATGCTTTGTGCTCTTTGATTTGCGATCTCCACCTTTGTATAG[A/C]TGAAAAATCTGAAACAGTATAGTAATAATATATCCAAATGGAAATATAACACCCCTA	9	771381	A	0.50
*MAL09-1111191	ATCAAAAAAACAATAGTAACATAATAAATAATATGTAATATTAAATAACTGTTCAAA[T/C]AAGGTGTCTAATAATGATTTTCGATGATGAAAAGGAGCATATTTTACACATGATGGAAT	9	1111191	G	0.44
*MAL10-113266	ATGTACATATTTTATTTTATTTTATTTTACATGTTGTTCATTTCTTTTTTGTGAG[T/C]ACATTTTAAAGGAGACACAAGATAAAAAATCATCGAATCTAAATATGATAACAATGTAG	10	113266	A	0.48
MAL10-317580	AAGGATGATGATCTTATAATAGATTTTATTAATCACTGTTAATGAATAATTTCTAT[T/T]GATGCCCAACAAGATAAGAAAAAATAAATTAAGATTGAACAGCAT	10	317580	T	0.37
MAL10-336274	AACCATATGACACCTAAGATGAATTTAATATTATGGAATATCTAATGTCTGATAATTAT[A/G]TTCATATTAATTTCTCCTCAAAGTTGTTTTAATACATTAACCTAAAAAATGAATTACATG	10	336274	A	0.46
MAL10-404541	AGATATGACCCCTATGGGCCCCTTTTGGTAAAGCAGGACCAATTCGACAGATAG[A/G]CCGTTGAATATCAAAATAAATTTCCCTCTTTTAAATATTTTTTATCTAAAT	10	404541	G	0.49
MAL10-631275	TGGCTTAGATCAATCATATTTCATTTACTTGTTCTTCTTCTTTTAAATATAA[T/A/T]CATCATCAGGTAGAGAGAAATATCATCATATAATTTCAATTTCAATAGGATATATGCTTTTT	10	631275	T	0.22
*MAL10-663198	TACTATAACCATCATATCCGTAAGTATAGAATATGATGTGCGTAATCATCTGTGCGCTT[T/G]AGTATACACATGCCATCTTCATCTACACCTACATTTTGAATATTCTACAAAATGATCAT	10	663198	A	0.26
MAL10-1300115	TAATAAATGTAAATAATCAATAAATAATAGAAGATCGATGAAATGTAAAGGATATACA[A/C]CTTGTTGATGGTTCGCAAAAAAATAATACAAAATGAGGAATATACATGATGATAACCAA	10	1300115	T	0.19
*MAL10-1385891	TAATAATATAACCGTTAATGCAATCATTTCCACATGTACGTAAAGAAATATTACATTTCC[T/C]ATAGAAGAAAGATTTCCACAGGAACCTTTAATCAAGGAAAAAATTATAAACACTGTGT	10	1385891	A	0.30
MAL11-185094	GTATATCCATTTTGGGATATATTCGGAATCAAAATAAAATACAATATCAGCAGTCGTTA[A/G]GTTAATACCAATACCACAGGCTCTGTAAGATAAATGAAGAAATAAATATTACTATTCGG	11	185094	A	0.43
MAL11-255830	CCATAAATAATTCATCTCGCTGTTATGTTTAAATATCAATTAATGTTGTGCTCTCA[A/G]GGTAGCTAAAAATTCGTAAGTGGTCTAATAATAACATAGCAAAATCTTAGAGATGACTGTAT	11	255830	G	0.47
*MAL11-281726	ATTATGTAATCTCTTTTAACTTTAGATTTTATACCTATACGCAACACATCTCTAATAT[T/C]AAATCTTCAACACATTTTCTTAAGATATTATCAACACTTACATGCTAGGACCTGTTACT	11	281726	A	0.37
*MAL11-304323	TTATAATAGTGTGCAATATTTCCTCTTTTAACTGCTTCTGCTACT[T/C]CTTTCTTATCTCTCATCTTCATTTCTTTTTTTCATATTTCATATTATAC	11	304323	G	0.14
*MAL11-683964	AATAGCTAGTCCAATTTTCATGACCATCAACAGGTAAATTTCCGCTGTTATTTCGCAAAACAT[T/C]TTTTGTGTGTGCAAAAAATAAACACAGCATTTACGCTTAGTACAAATTTTGGCATCAAAAA	11	683964	G	0.40
MAL11-769993	CCATGTGAATATAATATTGTCTGTTTTTAAATCCAAAGGTTTCTTATATAACATATA[A/C]CAGATCTCTCCGTCGAACCTCTTTTATGTTTTTATAATTTTATATGATATTAATTAATCT	11	769993	A	0.15
MAL11-896199	CTATGTGATCATCTCACAGCTTTGTGATAATTCACATTTTCCATCCAC[A/G]TTTTGTAGATTCATATTGTTGTAACAGTATGAGATCTTTTATATAGTACT	11	896199	A	0.23
MAL11-1331758	TTTTTTATGAAGCAAAAAAATAAATCTAAATCAAAATATGAACAAAGATGATTATTAT[A/G]CCGATTCGGATCAAGAGAAATATGCAAAATGAATCCGATGGAATAATATTATTCTGTT	11	1331758	A	0.39
MAL11-1520975	CAAAAAATGAAAAATTTACTATACAGAAACCAATATGGAATATAAATCAATCAGGAAAAA[A/T]GTGAGCGGAAGAGATTTAGATTTAGAAAGAGATGAAGATAAACATGATGCTCCACCGT	11	1520975	A	0.29
MAL11-1749804	ACAGCTCTGGAATAAATCTCACTACCTCACTATAACCAAAATTTTACCTGA[A/G]CACCTTTATATCATCTTTTGGAGGATTTTGGCAACATACACATCTTGAT	11	1749804	A	0.29
MAL11-1802198	TTCTAGTACCTGTCAGATAGATTTGGGAATCTGATTTAAATCACTGTGTGGCTATTTTTTTG[A/G]GATAAAATTTCTAGTGTGCTGACTTCTACTCTATGACAAATTAACCAAGGCTGATTAAT	11	1802198	A	0.32
*MAL12-83177	TCTTTTCTTCTGCTGTTATTTTGAATATTCAGTCTCATCATCTCTTTTTTAAATAT[T/C]AAATGCATAATAGCGATTTTAAATATCGCCTCTCTTATATGTTCTTTTCTTATATG	12	83177	G	0.15
*MAL12-114173	TACTTATGGAAAAATAGAAAAAGACTTTGCTTTGATTAATGCTAGATTGGAGACCTACATA[T/C]ATAAAAAATCATTCAGGTTTTTAAATGATAATCCATATATATAAATGAATAAGTATAT	12	114173	A	0.18
*MAL12-262199	TATATGAATTTATTTTATTTATTTATTTCTTTTTTAAAGATTTGGATAA[A/G]CCGGAAGAAGACTTACAGAAGATCCGAATTTGTAGACCTCAAAACAAAT	12	262199	nd	nd
MAL12-529412	TCGCCCAAGTTCATCATGTGATGATCAAGAGGTTTTTATTCCTTTTGGCCTACACATG[T/C]ATTTTCATCAAGTGTAAATACCAACCATCAACCATCTTGTCATTTCTTAAATCTGG	12	529412	A	0.29
*MAL12-1116275	ATATGTTATTTTCTATTTTTTTGTGTGCTCTTTTTTGTGTTGCACTATCTTGATTAATAT[T/C]TCTAATGTCCGTTGTGCACGTGGATGAATGAAGTTTGTGAAATTTTCTTTTTTTTAT	12	1116275	G	0.48
MAL12-1131597	CTTTTTCATGTCATATAATTTTCTTCATCATTTTATTTTATCATTTTGTGTGCGAATTTATC[T/C]TTTTTTATATTTTCCAAATCTTCCACATATACATATTTTTTGGATATATTACTCTCCG	12	1131597	G	0.34
*MAL12-1156125	AACAATATGATGATGTTTGAAGAAGACATACACATGACATGAACCCAGA[T/C]GATAAATATTGAGAAATATTTTCCAAATCTTGTAGTGTGATAGAGGTAAT	12	1156125	A	0.35
*MAL12-1591944	GACTCAACAGCATTTTATCATAAATAAATCACCAGCATATACCGCATTTTACATGATTA[T/C]TAATAGGATATTTCCTCAATATATGACAAAATATAAGATTCTGTGAT	12	1591944	G	0.37
*MAL12-1761553	ACATTTATATTATTTATATATCATCTACTATTATGTTTATCGCATCTTCAGATATATG[T/C]ATCCAGTTGGTGCTATTATTTCTCTCATCATATTTATCAACATATCATCTCTTAACATAC	12	1761553	G	0.29
MAL12-2046727	TTCCAATTTATATGTTATTTTAAATGATAAAAAAGACCATCTTTATGATTTGTTAT[A/G]TCTAATAAGGAATGAGAATGTGCAAAAAATTTTATTATTAATTTTTTAGTAACATCTATA	12	2046727	G	0.47
MAL13-146947	TTATTTTATTTGTTATCTCAACCAAAAAAATAGCTGTAAAGAAATTTTGAATAGATT[A/G]AACGATGACTAAATGAAGAAATATGTTGGTTATCAAAATAGGTTTGAAGAAATCGTATTTT	13	146947	G	0.39
*MAL13-210569	TAATAATTTATACATATCACTCAATTTGATTTATCTGCTATAAAATCCGATATTTCTTTTTT[C/C]CTTTTATCTATCTCTTTCTCTCCGCCCTTACTATTATGATATTCTCTTAACC	13	210569	A	0.29
MAL13-619422	TTTTTTCAGAGCCTGCAACTTTCCAGGTGAACCTACCTTAATATTACCA[A/G]TCCCTTTTTTATTAATATATAAGGGTATGATGATATTTCTTGTAATAAT	13	619422	A	0.46
*MAL13-1233419	TTTACATAATTTTCGACGCTCATCTTTTCATTATTACTCATAAATGGAATATCCACAATG[T/C]TTGCCCTCTTTACAGCTTTACAAAGTTGGTAAAAAATATGATAATCTCTTCCACCTCTTT	13	1233419	A	0.34
MAL13-1966774	CGTGTACATTTTATAAACCTTAAATCAATTAAGTCTCAGGTTTTTTTTTA[A/G]TATACCACATTTTCACTGTAATTTTTCACAGCAATTTGTGAAAAAGTCTT	13	1966774	A	0.29

MAL13-2158308	TTATTTTGTGTTGAATATATATTCAACTCTTTGATGTCATGTTCTGAAATTTTAAAGTAA[A/T]CTTTTGTGTTTATTCATGTCATTTTCTTGTCAGTTCGTTTCATATATTGATTTTGCA	13	2158308	A	0.26
MAL13-2570163	TATTAAATTTAAAGAATTTTTGAGTTCAAAAAAGTATTTCATCTAAATTATGATTTTC[A/C]ATTATTGATTTAAACATTGATCAGAAAGCAGTTCTTAGAGAAATTAAATATTTCATTATCT	13	2570163	A	0.46
*MAL14-990875	AGTAGTGTCTATAACAACATGCATCATAATAAATCATCAAGAAAAATTA[T/C]AGAAATCAAAACAGCTATAGCCACTTTTCTGGTCATGGTAGCTATATCGA	14	990875	G	0.32
MAL14-1199184	TACAGTATATACTTTTAATATCTGTACCAAAGGTAGATAAAAAATTCCTCATATATATATGT[A/T]CCATTAGTTCGAACTTTATGTATTTCTGGACAATATTCACTACTCCTATCCTTAATTTTA	14	1199184	A	0.38
MAL14-1458321	TAGTTGAATATGCTGAAGAGGTAGAATTAAGAAGAAGGTTGAAAAACATTTATGGGAG[A/G]AAAAGTTAATATGACAGAGAATCGCAGTGTTTTACATACAGCTTTAAGAATACCCATAGA	14	1458321	G	0.45
MAL14-1757546	AGAGGTACATATTTAATAGATTTTTTAAATGAAAAATAGTAATAAAAAATAATGTAACGCATG[A/G]TGATAGTGTATTACCAAATGGTAATGAAACGGACGCGAAAAAATGTGGATGAGAATAA	14	1757546	A	0.32
MAL14-1853537	ATATGCTCGTATATCATTCAAAATATTAAAGATGCATGATTATATCTGTAATAAGATGAGT[A/G]ACATTTATAAATACACAATTCAATTTTTTAACATTTCAACAGGACTATTATTTCAGGTAT	14	1853537	A	0.36
MAL14-3017684	ACACATCCAGAGGAGAGTATTTTCATCTTGAATAAGTCATCCGTTAAACATTCTGAAGAG[A/T]AGATCTATCTTCTTCTTATCCAATAAAACATTTTCTCTCGGTTTCATATCATGAAGCGG	14	3017684	T	0.37
MAL14-3124926	TGTGAAGAAGAAAAAGAATTAAATGGGAGCAGCTGGAGGAAGATATGTCGAAGAAGAGGTA[C/G]AGGGAGCAGTTGGAGGAAGAAATGTGGATGAAGAGGTAGAGGGAGCAGTTGGAGGAAGAA	14	3124926	C	0.34

Appendix 3. Age structure of patient population

Age category (yrs)	Frequency	Percent
<5	666	20.8
5-15	1109	34.63
≥15	1427	44.57
Total	3202	100

Appendix 4. Multiple regression analysis of t1/2P, stratified by location. Locations (from North to South) are Maela (MLA), Wang Pha (WPA), Mae Khon Ken (MKK) and Mawker Thai (MKT). The influence of patient age, prior malaria exposure, gender and sampling date on log t1/2P were examined using least squares regression in (A) all samples and (B) only patients with clearance data showing a good fit to a linear model ($r^2 \geq 0.8$). In both analyses sampling date strongly influences t1/2P in three of the four locations (black shading, white text). Significance of associations with patient age, gender and malaria exposure do not fall below $p=0.025$ and fail to reach Bonferroni corrected table-wide significance levels ($0.05/16=0.003$) in both analyses.


(A) t1/2P measures calculated from slopes with $r^2 > 0.8$ only

	MLA	n=433	WPA	n=1244	MKK	n=141	MKT	n=931
	F	p	F	p	F	p	F	p
Admission Date	82.834	8.9E-20	12.678	3.7E-04	0.943	0.332	14.123	1.7E-04
Age (yrs)	1.440	0.230	2.686	0.101	0.232	0.630	0.005	0.944
Malaria exposure ¹	0.016	0.899	2.457	0.117	0.287	0.592	4.512	0.034
Gender	3.301	0.069	0.639	0.424	1.827	0.176	0.748	0.387


(B) All data

	MLA	n=444	WPA	n=1346	MKK	n=150	MKT	n=1038
	F	p	F	p	F	p	F	p
Admission Date	79.154	5.7E-19	13.430	2.5E-04	0.292	0.589	13.572	2.3E-04
Age (yrs)	1.722	0.189	1.121	0.290	0.441	0.507	0.341	0.559
Malaria exposure ¹	0.003	0.956	4.086	0.043	0.255	0.614	3.945	0.047
Gender	5.006	0.025	0.661	0.416	2.605	0.107	0.028	0.867


¹Malaria exposure was defined by a documented malaria episode prior to the current episode.




Appendix 5. Genotyping data for one SNP. A typical SNP graph for the A/T SNP on chromosome 13, position 2158308, showing clustering of samples based on their genotypes. Genotype calls are made based on the normalized ratio of fluorescence intensity signals for the “A” and the “B” allele in the sample. The X-axis shows Norm Theta values, which correspond to the composition of the “B” allele in each sample. Multiple-clone infections are easily identified and were excluded from CR heritability analysis.




Appendix 6. Sampling breakdown for epidemiology and genetic analyses. Exclusion criteria are detailed in the text. The flow chart details how parasites with identical 93-locus genotypes infecting multiple patients were identified in the data set.



Appendix 7. Genetic relatedness among parasites. The tree shows the relatedness among 148 93-locus parasite genotypes infecting 441 patients. Blue genotype labels indicate infections collected between 2001 and 2004, black labels those collected from 2007-2010, while red labels show 30 infections from Cambodia. The numbers of patients infected with each genotype are shown in square brackets.



Appendix 8. Change in heritability of clearance rates on the Thai-Myanmar border. The proportion of variation in $t_{1/2}$ P that is due to parasite genetic factors (heritability) is shown for 2001-4 and 2007-10 time windows. Grey bars show heritability of $t_{1/2}$ P, while white bars show heritability analysis of residuals after removing effects of significant covariates. The error bars are 1 SD. The increase in heritability observed between 2001-4 and 2007-10 periods were tested by permutation (Appendix 9) and were significant for both $t_{1/2}$ P ($p < 0.01$) and residuals ($p = 0.04$).



Appendix 9. Permutation-based comparison of heritability in 2001-4 and 2007-10. In 2001-4, 29 groups of patients are infected with indistinguishable parasite genotypes, while in 2007-10, there were 119 groups. We randomly resampled 250 patients from 2007-10 generating samples containing on average 29 parasite genotypes infecting >1 patient. This resampling exercise provides a direct comparison with the 2001-4 period. Heritability estimates from 100 resampled 2007-10 datasets (range=0.48-0.85 exceeded that observed in 2001-4, demonstrating that the observed increase in H^2 is significant ($p < 0.01$). For residuals (following removal of effects of covariates) all but 4 resampled datasets exceeded H^2 values for 2001-4 ($p = 0.04$). These analyses are shown below. The frequency distribution shows H^2 values from 100 resampled 2007-10 datasets for A. $t_{1/2}P$ measures and B. residuals.